Details of the SBP
General Information of Synthetic Binding Protein (SBP) (ID: SBP000147) | ||||||
---|---|---|---|---|---|---|
SBP Name |
BiTE AMG-562
|
|||||
Synonyms |
AMG562
|
|||||
Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
Highest Status | Phase I | |||||
Protein Scaffold Information of This SBP | ||||||
---|---|---|---|---|---|---|
Scaffold ID | PS018 | [1] , [2] | ||||
Scaffold Name | BiTE | |||||
Scaffold Class | Antibody fragment | |||||
Fold Type | Beta-Sheets + Loops | |||||
Binding Target(s) of This SBP (BTS) |
---|
BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
---|---|---|---|---|---|---|
T-cell surface glycoprotein CD3 | Binder | B-cell non-hodgkin lymphoma [ICD-11: 2B33.5]; Follicular lymphoma [ICD-11: 2A80]; Mantle cell lymphoma [ICD-11: 2A85.5] | N.A. | Amgen | [1] , [2] | |
B-lymphocyte antigen CD19 | Modulator | B-cell non-hodgkin lymphoma [ICD-11: 2B33.5]; Follicular lymphoma [ICD-11: 2A80]; Mantle cell lymphoma [ICD-11: 2A85.5] | N.A. | Amgen | [1] , [2] | |
Clinical Trial Information of This SBP | ||||||
---|---|---|---|---|---|---|
NCT03571828 | Click to show the Detail | |||||
Indication | Relapsed or Refractory Diffuse Large B-cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma | |||||
Phase | Phase I | |||||
Title | A Phase I, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of?AMG 562?in Subjects With Relapsed / Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma | |||||
Status | Active, not recruiting | |||||
Sponsor | Amgen | |||||